Member Posts > Cardiol Therapeutics Unveils Promising Pre-Clinical Data on CRD-38 for Heart Failure Treatment
Millions of patients suffer from heart failure with preserved ejection fraction (HFpEF), a condition with high mortality and limited treatment options. Now, Cardiol Therapeutics is at the forefront of innovation with CRD-38, a subcutaneous therapy that has demonstrated extraordinary potential in pre-clinical research.
Key Study Findings
• Significant Improvement in Cardiac Function: CRD-38 enhances ejection fraction and cardiac output, allowing better blood circulation.
• Reduction in Structural Damage: The drug reduces hypertrophy and fibrosis, two major contributors to HFpEF progression.
• Potent Anti-Inflammatory Effects: CRD-38 lowers pro-inflammatory cytokines, which are key drivers of heart failure-related damage.
• Mitochondrial Protection: The treatment helps preserve cellular energy production, preventing metabolic stress in heart cells.
A Unique Approach to Heart Failure
Unlike existing HFpEF treatments, which primarily manage symptoms, CRD-38 directly targets the underlying causes of heart failure, including inflammation, oxidative stress, and cardiac remodeling.
With clinical development on the horizon, Cardiol Therapeutics is positioning CRD-38 as a potential game-changer in the treatment landscape for HFpEF.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs